## Mei-Ling Han

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2807240/publications.pdf Version: 2024-02-01



MELLING HAN

#	Article	IF	CITATIONS
1	A polytherapy based approach to combat antimicrobial resistance using cubosomes. Nature Communications, 2022, 13, 343.	5.8	31
2	Comparative metabolomics revealed key pathways associated with the synergistic killing of multidrug-resistant Klebsiella pneumoniae by a bacteriophage-polymyxin combination. Computational and Structural Biotechnology Journal, 2022, 20, 485-495.	1.9	12
3	A synthetic lipopeptide targeting top-priority multidrug-resistant Gram-negative pathogens. Nature Communications, 2022, 13, 1625.	5.8	53
4	Correlative proteomics identify the key roles of stress tolerance strategies in Acinetobacter baumannii in response to polymyxin and human macrophages. PLoS Pathogens, 2022, 18, e1010308.	2.1	6
5	An Intelligent Strategy with All-Atom Molecular Dynamics Simulations for the Design of Lipopeptides against Multidrug-Resistant <i>Pseudomonas aeruginosa</i> . Journal of Medicinal Chemistry, 2022, 65, 10001-10013.	2.9	6
6	Comparative metabolomics reveals key pathways associated with the synergistic activity of polymyxin B and rifampicin combination against multidrug-resistant Acinetobacter baumannii. Biochemical Pharmacology, 2021, 184, 114400.	2.0	16
7	Polymyxin-Induced Metabolic Perturbations in Human Lung Epithelial Cells. Antimicrobial Agents and Chemotherapy, 2021, 65, e0083521.	1.4	3
8	Lipid A profiling and metabolomics analysis of paired polymyxin-susceptible and -resistant MDR <i>Klebsiella pneumoniae</i> clinical isolates from the same patients before and after colistin treatment. Journal of Antimicrobial Chemotherapy, 2020, 75, 2852-2863.	1.3	14
9	Metabolic Perturbations Caused by the Over-Expression of mcr-1 in Escherichia coli. Frontiers in Microbiology, 2020, 11, 588658.	1.5	7
10	Outer Membranes of Polymyxin-Resistant <i>Acinetobacter baumannii</i> with Phosphoethanolamine-Modified Lipid A and Lipopolysaccharide Loss Display Different Atomic-Scale Interactions with Polymyxins. ACS Infectious Diseases, 2020, 6, 2698-2708.	1.8	19
11	Phytantriol-Based Cubosome Formulation as an Antimicrobial against Lipopolysaccharide-Deficient Gram-Negative Bacteria. ACS Applied Materials & Interfaces, 2020, 12, 44485-44498.	4.0	12
12	Molecular dynamics simulations informed by membrane lipidomics reveal the structure–interaction relationship of polymyxins with the lipid A-based outer membrane of <i>Acinetobacter baumannii</i> . Journal of Antimicrobial Chemotherapy, 2020, 75, 3534-3543.	1.3	25
13	Mitochondrial dysfunction caused by outer membrane vesicles from Gram-negative bacteria activates intrinsic apoptosis and inflammation. Nature Microbiology, 2020, 5, 1418-1427.	5.9	105
14	Polymyxins Bind to the Cell Surface of Unculturable <i>Acinetobacter baumannii</i> and Cause Unique Dependent Resistance. Advanced Science, 2020, 7, 2000704.	5.6	31
15	Polymyxin resistance in Klebsiella pneumoniae: multifaceted mechanisms utilized in the presence and absence of the plasmid-encoded phosphoethanolamine transferase gene mcr-1. Journal of Antimicrobial Chemotherapy, 2019, 74, 3190-3198.	1.3	12
16	Comparative Metabolomics Reveals Key Pathways Associated With the Synergistic Killing of Colistin and Sulbactam Combination Against Multidrug-Resistant Acinetobacter baumannii. Frontiers in Pharmacology, 2019, 10, 754.	1.6	21
17	Synergistic Combination of Polymyxin B and Enrofloxacin Induced Metabolic Perturbations in Extensive Drug-Resistant Pseudomonas aeruginosa. Frontiers in Pharmacology, 2019, 10, 1146.	1.6	17
18	Metabolomics Study of the Synergistic Killing of Polymyxin B in Combination with Amikacin against Polymyxin-Susceptible and -Resistant Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2019, 64, .	1.4	28

Mei-Ling Han

#	Article	IF	CITATIONS
19	Novel Polymyxin Combination with the Antiretroviral Zidovudine Exerts Synergistic Killing against NDM-Producing Multidrug-Resistant Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2019, 63, .	1.4	16
20	Comparative Metabolomics and Transcriptomics Reveal Multiple Pathways Associated with Polymyxin Killing in Pseudomonas aeruginosa. MSystems, 2019, 4, .	1.7	52
21	Fitness cost of mcr-1-mediated polymyxin resistance in Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy, 2018, 73, 1604-1610.	1.3	68
22	Polymyxin B in Combination with Enrofloxacin Exerts Synergistic Killing against Extensively Drug-Resistant Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	15
23	Alterations of Metabolic and Lipid Profiles in Polymyxin-Resistant Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	58
24	Structure, Function, and Biosynthetic Origin of Octapeptin Antibiotics Active against Extensively Drug-Resistant Gram-Negative Bacteria. Cell Chemical Biology, 2018, 25, 380-391.e5.	2.5	57
25	Comparative analysis of phosphoethanolamine transferases involved in polymyxin resistance across 10 clinically relevant Gram-negative bacteria. International Journal of Antimicrobial Agents, 2018, 51, 586-593.	1.1	18
26	Mechanism-Based Pharmacokinetic/Pharmacodynamic Modeling of Aerosolized Colistin in a Mouse Lung Infection Model. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	12
27	Emergence of High-Level Colistin Resistance in an Acinetobacter baumannii Clinical Isolate Mediated by Inactivation of the Global Regulator H-NS. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	36
28	Genome-scale metabolic modeling of responses to polymyxins in <i>Pseudomonas aeruginosa</i> . GigaScience, 2018, 7, .	3.3	44
29	Polymyxin-Induced Lipid A Deacylation in <i>Pseudomonas aeruginosa</i> Perturbs Polymyxin Penetration and Confers High-Level Resistance. ACS Chemical Biology, 2018, 13, 121-130.	1.6	59
30	Elucidating the Pharmacokinetics/Pharmacodynamics of Aerosolized Colistin against Multidrug-Resistant Acinetobacter baumannii and Klebsiella pneumoniae in a Mouse Lung Infection Model. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	11
31	Metabolic Analyses Revealed Time-Dependent Synergistic Killing by Colistin and Aztreonam Combination Against Multidrug-Resistant Acinetobacter baumannii. Frontiers in Microbiology, 2018, 9, 2776.	1.5	20
32	Mechanistic Insights From Global Metabolomics Studies into Synergistic Bactericidal Effect of a Polymyxin B Combination With Tamoxifen Against Cystic Fibrosis MDR Pseudomonas aeruginosa. Computational and Structural Biotechnology Journal, 2018, 16, 587-599.	1.9	19
33	A Comparative Study of Outer Membrane Proteome between Paired Colistin-Susceptible and Extremely Colistin-Resistant <i>Klebsiella pneumoniae</i> Strains. ACS Infectious Diseases, 2018, 4, 1692-1704.	1.8	15
34	Lipidomic Analysis of the Outer Membrane Vesicles from Paired Polymyxin-Susceptible and -Resistant Klebsiella pneumoniae Clinical Isolates. International Journal of Molecular Sciences, 2018, 19, 2356.	1.8	23
35	Plasma Protein Binding Structure–Activity Relationships Related to the N-Terminus of Daptomycin. ACS Infectious Diseases, 2017, 3, 249-258.	1.8	20
36	Characterization of the Polymyxin D Synthetase Biosynthetic Cluster and Product Profile of <i>Paenibacillus polymyxa</i> ATCC 10401. Journal of Natural Products, 2017, 80, 1264-1274.	1.5	27

Mei-Ling Han

#	Article	IF	CITATIONS
37	From Breast Cancer to Antimicrobial: Combating Extremely Resistant Gram-Negative "Superbugs―Using Novel Combinations of Polymyxin B with Selective Estrogen Receptor Modulators. Microbial Drug Resistance, 2017, 23, 640-650.	0.9	45
38	Investigating the Interaction of Octapeptin A3 with Model Bacterial Membranes. ACS Infectious Diseases, 2017, 3, 606-619.	1.8	25
39	A Fresh Shine on Cystic Fibrosis Inhalation Therapy: Antimicrobial Synergy of Polymyxin B in Combination with Silver Nanoparticles. Journal of Biomedical Nanotechnology, 2017, 13, 447-457.	0.5	12
40	Global metabolic analyses identify key differences in metabolite levels between polymyxin-susceptible and polymyxin-resistant Acinetobacter baumannii. Scientific Reports, 2016, 6, 22287.	1.6	49
41	An "Unlikely―Pair: The Antimicrobial Synergy of Polymyxin B in Combination with the Cystic Fibrosis Transmembrane Conductance Regulator Drugs KALYDECO and ORKAMBI. ACS Infectious Diseases, 2016, 2, 478-488.	1.8	80